RxDoctor Payments DataLook up a doctor →

Peter McAllister

Neurology · Fairfield, CTNPI 1033176896

Payments from drug & device makers

$14,987,595in general payments, 2019–2025

Across 6,459 payments — averaging $2320.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$5.4M
  • AbbVie$1.5M
  • H. Lundbeck A S$1.1M
  • Ipsen Innovation$965K
  • Genentech, Inc.$772K
  • Amgen$553K
  • plus $4.7M from 54 others
$77,292in research payments, 2019–2025

Across 37 payments — averaging $2088.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$40K
  • Eli Lilly$34K
  • Novartis$2K
  • AbbVie$658
  • Merz North America, Inc.$630

What the payments were for

  • Consulting fees$558,06624%
  • Speaking & faculty fees$1,362,47359%
  • Grants$880%
  • Travel & lodging$296,68213%
  • Food & beverage$83,4314%
  • Education$5490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly87$5,373,733
AbbVie(2 entities)1,164$1,526,325
H. Lundbeck A S180$1,069,073
Ipsen Innovation476$965,000
Genentech, Inc.75$772,463
Amgen(2 entities)280$553,446
Novartis177$537,247
Lilly USA, LLC537$467,436
Merz Pharmaceuticals, LLC49$360,931
Biohaven Pharmaceutical Holding Company Ltd.134$325,467
E.r. Squibb & Sons, L.L.C.11$286,473
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)39$282,556
Teva Pharmaceuticals USA, Inc.187$262,104
Eisai Inc.160$233,409
Pfizer(2 entities)220$227,096
Sunovion Pharmaceuticals Inc.45$216,019
Ipsen Pharma SAS65$195,562
UCB SA5$177,470
Biogen53$167,537
Lundbeck LLC178$163,806
Impel Pharmaceuticals Inc.136$115,363
Upsher-smith Laboratories LLC97$107,931
Biohaven Pharmaceuticals, Inc.77$100,028
Alkermes, Inc.24$87,801
MDD US Operations, LLC378$79,555
EMD Serono, Inc.72$77,765
ANI Pharmaceuticals, Inc.78$41,270
Axsome Therapeutics, Inc.62$39,904
Merz North America, Inc.20$21,837
Sanofi39$19,667
Currax Pharmaceuticals LLC31$18,289
Biodelivery Sciences International, Inc.19$14,534
Dompe US, Inc.9$14,348
Avanir Pharmaceuticals, Inc.52$13,961
Novartis Pharma AG7$13,821
Acadia Pharmaceuticals Inc8$12,630
Promius Pharma LLC17$5,364
Evoke Pharma, Inc.2$4,308
Bausch Health US, LLC26$3,655
Amneal Pharmaceuticals LLC115$3,329
Neurocrine Biosciences, Inc.75$3,233
Collegium Pharmaceutical, Inc.12$2,515
Genentech USA, Inc.101$2,036
Tonix Medicines, Inc.3$2,032
Scilex Pharmaceuticals Inc.24$1,785
CSL Behring118$1,625
UCB, Inc.65$1,497
Acorda Therapeutics, Inc14$1,422
Neurelis, Inc.35$1,240
Argenx US, Inc.50$1,206
Harmony Biosciences LLC50$1,041
Takeda Pharmaceuticals U.S.A., Inc.61$981
SK Life Science, Inc.47$826
Bristol Myers Squibb52$696
Ipsen Biopharmaceuticals, Inc23$659
Jazz Pharmaceuticals Inc.25$446
Grifols USA, LLC20$424
Mallinckrodt Hospital Products Inc.13$357
Supernus Pharmaceuticals, Inc.29$302
Xeris Pharmaceuticals, Inc.15$301

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,987,595 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4636$450,223
OctagamImmun Globg(Igg)/Malt/Iga Ov5035$417,122
BotoxOnabotulinumtoxina60$80,084
QuliptaAtogepant46$67,562
VyeptiEptinezumab-Jjmr13$61,183
UbrelvyUbrogepant23$34,402
AptiomEslicarbazepine Acetate12$23,968
TrintellixVortioxetine Hydrobromide34$21,811
Aimovig AutoinjectorErenumab-Aooe23$21,163
Emgality PenGalcanezumab-Gnlm23$16,257
KeppraLevetiracetam11$15,828
Sumatriptan Succinate92$10,580
Zolmitriptan12$7,888
BelsomraSuvorexant13$5,559
Duloxetine Hcl73$1,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$424$450,22336 claims
PfizerOctagam$227,096$417,12235 claims
AbbVieBotox, Qulipta, Ubrelvy$1,526,325$182,048129 claims
Lundbeck LLCVyepti$163,806$61,18313 claims
Sunovion Pharmaceuticals Inc.Aptiom$216,019$23,96812 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$981$21,81134 claims
UCB SAKeppra$177,470$15,82811 claims
Upsher-smith Laboratories LLCTopiramate$107,931$67232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.

Other neurology in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →